Up & Down Wall St.

Randall W. Forsyth

By roiling the markets, it and other European financial institutions could jack rates, hurting the global economy.

Streetwise

Ben Levisohn

The group has become riskier, but some of its members, including Johnson & Johnson, Amgen, Medtronic, Allergan,and Lilly, are still worth a look.

Trader Extra

Jack Hough

If CBS and Viacom strike a deal, CBS chief Les Moonves will have an outsize say over the terms.

Feature

Robert Guy

Four market pros share their outlook for Asia and their best investment picks. Bullish on India.

Editorial Commentary

Thomas G. Donlan

A movement aims to undo past “Progressive” policies with a general reconsideration of the Constitution.

The Trader

Lawrence C. Strauss

The market finished an up-and-down week on a positive note, helped by a strong showing from energy stocks.

Trader Extra

Bill Alpert

Off Wall Street Research analyst Mark Roberts has flagged many stocks not worth buying.

International Trader - Europe

Jonathan Buck

The German utility has struggled with weak energy pricing and a bill to decommission nuclear plants. Its answer: Break the company in two.

International Trader - Asia

Shuli Ren

State-owned Bank Mandiri is a designated gateway for funds returning to Indonesia. But the benefit may be small and its problems look large.

Emerging Markets

Dimitra DeFotis

Through the first three quarters, Latin stocks have soared while Greek and Chinese shares have fallen.

Current Yield

Amey Stone

Investors should look at business development companies, publicly traded firms that buy loans.

The Striking Price

Steve Sosnick

Need to protect yourself against, say, a Trump victory? Take out an insurance policy of options.

Commodities Corner

Chelsey Dulaney

A surge in U.S. demand has produced an oversupply. Prices are likely to fall further.

Technology Trader

Tiernan Ray

As dominant as they are today, Alphabet and Facebook could lose out to new ways of delivering advertising.

Fund of Information

Lewis Braham

Managers’ drive to gather assets means successors to closed funds will keep popping up even if they hurt returns.

ETF Focus

Chris Dieterich

It’s a good time for investors to consider biotech ETFs that hold smaller drugmakers.

Speaking of Dividends

Lawrence C. Strauss

Most of these stocks remain quite cheap, but investors need to approach them carefully. The problem: growth challenges.

Balancing the Books

Gene Epstein

Andrew Bacevich writes a riveting history of U.S. military misadventures in Afghanistan, Iraq, and elsewhere. Also, a meditation on mortality’s benefits.

Economic Beat

Gene Epstein

Both Hillary Clinton and Donald Trump misstated realities in the first of their televised face-offs.

Review

Nothing quite compares to the powerful inverse correlation between the odds of a Trump victory and the Mexican currency’s value.

Preview

The Deepwater Horizon disaster gets the Hollywood treatment as a disaster film of the same name.